Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21065478 | 0.82 | PNMT (0.39) | PNMT | |
| SCHEMBL25060977 | 0.80 | MTNR1A (0.32) | MTNR1A | |
| SCHEMBL23329956 | 0.76 | PNMT (0.35) | CD44PNMT | |
| SCHEMBL21942491 | 0.72 | PNMT (0.37) | PNMT | |
| SCHEMBL21065635 | 0.71 | DRD2 (0.37) | PNMT | |
| SCHEMBL19705359 | 0.71 | CD44 (0.50) | CD44PNMT | |
| SCHEMBL10169291 | 0.70 | CD44 (0.56) | CD44PNMT | |
| SCHEMBL25085610 | 0.68 | CD44 (0.37) | CD44PNMTNMT1 | |
| SCHEMBL21659168 | 0.67 | ASIC3 (0.35) | PNMT | |
| SCHEMBL25085608 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | CD44 3525/4885PNMT 2699/4885NMT1 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.